The PCRopsis™ R&D team has been extremely diligent and successful in developing and validating direct PCR technologies for numerous applications. As such, we are expanding our business development team in the U.S., E.U. and Latin America.
Say tuned for future developments.
PCRopsis™ Reagent RVD was recently shown to mediate direct PCR amplification from viral and bacterial targets using low volumes of reagent and sample, thus drastically lowering costs and increasing testing accessibility.
Reagent RVD is a flexible direct PCR product for various research and clinical applications. The PCR testing industry is particularly price-conscious, with thin profit margins. As such, laboratories seek affordable and accurate solutions to offer clients the best services.
Recent miniaturization studies confirm Reagent RVD facilitates extraction-free RT-PCR and qPCR for less than the competition; especially when one factors in savings in time and consumable, that can translate to higher daily profits. Typically, the complete cost of RNA and DNA extraction kits cost $4.00 ~ $10.00 per extraction. Moreover, Reagent RVD even offers advantages over alternative direct PCR products currently on the market.
Reagent RVD advantages over alternative direct PCR products:
“It’s interesting how RNA and DNA extraction was mostly taken as a necessary first step in PCR applications for decades. It took the COVID-19 pandemic to get people questioning the validity of that presumption on a large scale. We see the development of affordable and robust direct PCR products as a means of making the PCR diagnostic industry more efficient and equitable”, said Obdulio Piloto, Ph.D., C.E.O. of Entopsis.
“Reagent RVD doesn’t just solve a key problem in the PCR industry, but also offers huge cost savings to partnering labs”, said Pratik Sharma, VP of business development at Entopsis.